Browsing by Author "Eralp, Yeşim"
Now showing items 1-9 of 9
-
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
Kılıçkap, Sadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Sakalar, Teoman; Uysal, Mükremin; Üskent, Necdet; Demir, Nurcan; Sakin, Ayşegül; Turhal, Nazım Serdar; Keskin, Serhat; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Karaca, Saziye; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan Uluç, Başak; Turna, Zeynep Hande; Küçüköner, Mehmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Şeker, Mesut; Ünal, Olçun Umut; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Duygu (Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study
Disel, Umut; Köse, Fatih; Bilici, Ahmet; Özgüroğlu, Mustafa; Sağlam, Sezer; Şeker, Mesut; Aksoy, Sercan; Tek, İbrahim; Eralp, Yeşim; Molinas Mandel, Nil; Demir, Gökhan; Arslan, Çağatay; Demiray, Mutlu; Salepçi, Taflan; Öztürk, Mehmet Akif; Selçukbiricik, Fatih; Temizaş, Gökçe; Fidan, Ebru Gül (American Society of Clinical Oncology, 2020)... -
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
Kılıçkap, Saadettin; Ölmez, Ömer Fatih; Cicin, İrfan; Demirci, Umut; Alan, O.; Çabuk, Devrim; Sakalar, Teoman; Tatlı, Ali Murat; Buğdaycı, F. Başol; Eralp, Yeşim; Uysal, Mükremin; Demirkazik, Ahmet; Bilgin, Burak; Yıldız, Birol; Karaağaç, Mustafa; Okutur, Kerem; Sakin, Ayşegül (Oxford University Press, 2018)… -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Science Inc, 2021)Introduction: Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Ireland Ltd, 2020)Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ... -
The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors
Dişel, Umut; Köse, Fatih; Bilici, Ahmet; Özgüroğlu, Mustafa; Sağlam, Sezer; Şeker, Mesut; Aksoy, Sercan; Tek, İbrahim; Mandel, Nil Molinas; Demir, Gökhan; Arslan, Çağatay; Demiray, Mutlu; Öztürk, Mehmet Akif; Salepçi, Taflan; Eralp, Yeşim; Selçukbiricik, Fatih; Temizaş, Gökçe; Fidan, Ebru Gül (Turkiye Klinikleri, 2022)Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact ... -
Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Kılıçkap, Saadettin; Buğdaycı Basal, Fatma; Demirkazık, Ahmet; Gürsoy, Pınar; Demirci, Ufuk; Erman, Mustafa; Yumuk, Fulden; Çay Şenler, Filiz; Çakar, Burcu; Çiçin, İrfan; Öztürk, Akın; Coşkun, Hasan Şenol; Çubukçu, Erdem; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Tatlı, Ali Murat; Karaağaç, Mehmet Onur; Sakalar, Teoman; Eralp, Yeşim; Korkmaz, Taner (Oxford University Press, 2019)Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who ... -
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
Kılıçkap, Saadettin; Demirci, Umut; Buğdaycı, Fatma; Tural, Deniz; Korkmaz, Taner; Paydaş, Semra; Yılmaz, Coşkun; Tuna, Hande; Sezer, Ahmet; Yeşil Çinkir, Havva; Erman, Münire; Eralp, Yeşim; Çabuk, Devrim; Işıkdoğan, Abdurrahman; Demirkazık, Ahmet; Karaoğlu, Aziz; Yazılıtaş, Doğan; Çay Şenler, Filiz; Yumuk, Perran Fulden; Coşkun, Hatice; Yıldız, İbrahim; Öztop, İlhan; Beypınar, İsmail; Aydın, Kübra; Kaplan, M.; Meydan, Nezih; Ölmez, Ömer Fatih; Seber, Samile; Arslan, Çağatay; Şendur, Mehmet Ali Nahit; Çiçin, İrfan (Elsevier Science, 2019)Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ...
